Radiopharm Theranostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Radiopharm Theranostics şirketinin toplam hissedar öz sermayesi A$27.4M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$72.0M ve A$44.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$18.58m
Eşitlik	AU$27.35m
Toplam yükümlülükler	AU$44.68m
Toplam varlıklar	AU$72.04m

Son finansal sağlık güncellemeleri

We're A Little Worried About Radiopharm Theranostics' (ASX:RAD) Cash Burn Rate

Jan 06

Here's Why Radiopharm Theranostics (ASX:RAD) Must Use Its Cash Wisely

Sep 02

Recent updates

We're A Little Worried About Radiopharm Theranostics' (ASX:RAD) Cash Burn Rate

Jan 06

Here's Why Radiopharm Theranostics (ASX:RAD) Must Use Its Cash Wisely

Sep 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RAD 'nin kısa vadeli varlıkları ( A$22.8M ) kısa vadeli yükümlülüklerini ( A$17.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: RAD 'un kısa vadeli varlıkları ( A$22.8M ) uzun vadeli yükümlülüklerini ( A$27.1M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RAD borçsuzdur.

Borcun Azaltılması: RAD un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RAD şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: RAD un, serbest nakit akışı her yıl % 18.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Radiopharm Theranostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're A Little Worried About Radiopharm Theranostics' (ASX:RAD) Cash Burn Rate

Here's Why Radiopharm Theranostics (ASX:RAD) Must Use Its Cash Wisely

Recent updates

Radiopharm Theranostics Limited, Annual General Meeting, Nov 25, 2024

New minor risk - Profitability

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Radiopharm Theranostics Appoints Dimitris Voliotis as Chief Medical Officer

New major risk - Shareholder dilution

Forecast to breakeven in 2027

New minor risk - Share price stability

New major risk - Market cap size

Radiopharm Theranostics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.693333 million.

Radiopharm Theranostics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.560297 million.

Radiopharm Theranostics Limited has filed a Follow-on Equity Offering in the amount of AUD 0.708 million.

Radiopharm Theranostics Limited has completed a Follow-on Equity Offering in the amount of AUD 10.107197 million.

New minor risk - Share price stability

Radiopharm Theranostics Limited, Annual General Meeting, Nov 16, 2023

Full year 2023 earnings released: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)

New minor risk - Financial data availability

Consensus revenue estimates fall by 27%

Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer

Radiopharm Theranostics Limited Appoints Dr. Rama Abu Shmeis as Senior Vice President, Chemistry and Manufacturing Controls

We're A Little Worried About Radiopharm Theranostics' (ASX:RAD) Cash Burn Rate

Radiopharm Theranostics Receives US Food and Drug Administration Investigational New Drug Application Approval for Its V6 Integrin (RAD301) Technology

Radiopharm Theranostics Announces Positive Imaging Data Has Been Published Regarding Its HER2 Nanobody (RAD201) in the Prestigious European Journal of Nuclear Medicine & Molecular Imaging

Radiopharm Theranostics Limited Announces Additional Data Released from Brain Metastases Imaging Trial

No independent directors

Radiopharm Theranostics Limited Announces Pivalate Achieves Positive Phase 2 Data in Brain Mets Trial

Radiopharm Theranostics Limited, Annual General Meeting, Nov 16, 2022

FDA Grants Rare Pediatric Disease Designation for Radiopharm Theranostics's DUNP19 for Osteosarcoma

Here's Why Radiopharm Theranostics (ASX:RAD) Must Use Its Cash Wisely

Radiopharm Theranostics Limited Appoints Susann Brady-Kalnay to Scientific Advisory Board

Radiopharm Theranostics Limited Appoints Leila Alland as Director

Radiopharm Theranostics Appoints Vittorio Puppo as Chief Operating Officer

No independent directors

Founder & Executive Chairman recently bought AU$56k worth of stock

Radiopharm Theranostics Limited Appoints Hester Larkin as Non-Executive Director, Effective from February 3, 2022

Radiopharm Theranostics Limited Appoints Hester Larkin as Non-Executive Director, Effective from February 3, 2022

Radiopharm Theranostics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.69535 million.

Radiopharm Theranostics Limited Acquires Ip Ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics Announces Completion of Phase 1 Imaging Study in Breast Cancer

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin